首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1489215

全球多種癌症早期檢測市場研究報告 - 2024 年至 2032 年行業分析、規模、佔有率、成長、趨勢和預測

Global Multi Cancer Early Detection Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年05月01日 | 出版商:

Value Market Research | 英文 122 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

預計到2032年，全球多癌症早期檢測市場的市場規模將從2023年的9.8956億美元達到近41.3801億美元，2024-2032年研究期間的複合年成長率為17.23%。

多種癌症早期檢測涉及使用先進的診斷技術同時或依序對個體進行多種類型的癌症篩檢。與傳統的單一癌症篩檢測試不同，多癌症檢測方法旨在在治療更有效的早期階段識別更廣泛的癌症類型。這些方法可能包括血液測試、成像技術和檢測與各種癌症相關的特定生物標記的分子測定。透過更早發現癌症，多種癌症篩檢可以針對個別患者採取及時介入和治療策略，從而提高存活率並降低癌症相關死亡率。

市場動態

全球癌症盛行率的不斷上升以及晚期診斷負擔的日益增加，凸顯了對更有效的篩檢方法的迫切需要，這些方法能夠在更早期、更可治療的階段檢測出多種癌症類型。此外，基因組和蛋白質組學技術的進步，包括下一代定序（NGS）、液體活體組織切片和腫瘤標記分析，使得高靈敏度和特異性的多種癌症早期檢測測試的開發成為可能，這些測試可以檢測循環腫瘤DNA（ctDNA）、蛋白質和其他指示血液樣本中各種癌症類型的生物標記。此外，擴大採用人工智慧和機器學習演算法進行資料分析和解釋，提高了多種癌症篩檢測試的準確性和可靠性，減少了誤報，並改善了診斷結果。此外，醫療保健提供者、政策制定者和公眾對早期癌症檢測重要性的認知不斷提高，加上篩檢測試報銷選項的可用性，正在推動對多種癌症早期檢測解決方案的需求，塑造市場的未來。然而，大規模實施多種癌症篩檢計畫的複雜性和成本，以及倫理考量和病患隱私問題，可能會在未來幾年挑戰多種癌症早期檢測市場的成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球多癌症早期檢測市場的各個細分市場進行了包容性評估。多種癌症早期檢測產業的成長和趨勢為這項研究提供了整體方法。

市場區隔

多癌症早期檢測市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按類型

液體活體組織切片
基因組 & LDT 其他

按最終用途

醫院
診斷實驗室
其他

區域分析

本節涵蓋區域展望，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲多癌症早期檢測市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。多重癌症早期檢測市場的主要參與者包括Illumina Inc. (GRAIL LLC)、Exact Sciences Corp.、Foundation Medicine Inc.、AnchorDx、Guardant Health、燃石生物科技有限公司、Genecast、北京萊曼君泰國際醫療技術發展有限公司.、Freenome Holdings Inc.、Elypta AB。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：多種癌症早期檢測公司的競爭格局

多種癌症早期檢測市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
Illumina Inc. (GRAIL LLC)

公司簡介
公司收入
產品
最近的發展

Exact Sciences Corp.

公司簡介
公司收入
產品
最近的發展

Foundation Medicine Inc.

公司簡介
公司收入
產品
最近的發展

AnchorDx

公司簡介
公司收入
產品
最近的發展

Guardant Health

公司簡介
公司收入
產品
最近的發展

Burning Rock Biotech Ltd.

公司簡介
公司收入
產品
最近的發展

GENECAST

公司簡介
公司收入
產品
最近的發展

Beijing Lyman Juntai International Medical Technology Development Co.

公司簡介
公司收入
產品
最近的發展

Freenome Holdings Inc.

公司簡介
公司收入
產品
最近的發展

Elypta AB

公司簡介
公司收入
產品
最近的發展

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112114514

The global demand for Multi Cancer Early Detection Market is presumed to reach the market size of nearly USD 4138.01 Million by 2032 from USD 989.56 Million in 2023 with a CAGR of 17.23% under the study period 2024-2032.

Multi cancer early detection involves screening individuals for multiple types of cancer simultaneously or sequentially using advanced diagnostic technologies. Unlike traditional single-cancer screening tests, multi-cancer detection methods aim to identify a broader range of cancer types at earlier stages when treatment is more effective. These approaches may include blood tests, imaging techniques, and molecular assays that detect specific biomarkers associated with various cancers. By detecting cancers earlier, multi-cancer screening can improve survival rates and reduce cancer-related mortality by enabling timely intervention and treatment strategies tailored to individual patients.

MARKET DYNAMICS

The spurring prevalence of cancer worldwide and the growing burden of late-stage diagnoses highlight the urgent need for more effective screening methods capable of detecting multiple cancer types at earlier, more treatable stages. Additionally, the advancements in genomic and proteomic technologies, including next-generation sequencing (NGS), liquid biopsy, and tumor marker analysis, have enabled the development of highly sensitive and specific multi cancer early detection tests that can detect circulating tumor DNA (ctDNA), proteins, and other biomarkers indicative of various cancer types in blood samples. Furthermore, the rising adoption of artificial intelligence & machine learning algorithms for data analysis and interpretation enhances the accuracy and reliability of multi-cancer screening tests, reduces false positives, and improves diagnostic outcomes. Moreover, the spurring awareness of the significance of early cancer detection among healthcare providers, policymakers, and the general public, coupled with the availability of reimbursement options for screening tests, is driving demand for multi-cancer early detection solutions, shaping the market's future. However, the complexity and cost of implementing multi-cancer screening programs on a large scale, along with ethical considerations and patient privacy concerns, may challenge the multi cancer early detection market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Multi Cancer Early Detection. The growth and trends of Multi Cancer Early Detection industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Multi Cancer Early Detection market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Liquid Biopsy
Gene Panel & LDT Others

By End-use

Hospitals
Diagnostic Laboratories
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Multi Cancer Early Detection market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Multi Cancer Early Detection market include Illumina Inc. (GRAIL LLC), Exact Sciences Corp., Foundation Medicine Inc., AnchorDx, Guardant Health, Burning Rock Biotech Ltd., Genecast, Beijing Lyman Juntai International Medical Technology Development Co., Freenome Holdings Inc., Elypta AB. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. MULTI CANCER EARLY DETECTION - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By End-use
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL MULTI CANCER EARLY DETECTION MARKET ANALYSIS BY TYPE

5.1. Overview By Type
5.2. Historical and Forecast Data
5.3. Analysis By Type
5.4. Liquid Biopsy Historic and Forecast Sales By Regions
5.5. Gene Panel & LDT Others Historic and Forecast Sales By Regions

6. GLOBAL MULTI CANCER EARLY DETECTION MARKET ANALYSIS BY END-USE

6.1. Overview By End-use
6.2. Historical and Forecast Data
6.3. Analysis By End-use
6.4. Hospitals Historic and Forecast Sales By Regions
6.5. Diagnostic Laboratories Historic and Forecast Sales By Regions
6.6. Others Historic and Forecast Sales By Regions

7. GLOBAL MULTI CANCER EARLY DETECTION MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE MULTI CANCER EARLY DETECTION COMPANIES

8.1. Multi Cancer Early Detection Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF MULTI CANCER EARLY DETECTION INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Illumina Inc. (GRAIL LLC)
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Exact Sciences Corp.
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Foundation Medicine Inc.
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. AnchorDx
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Guardant Health
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. Burning Rock Biotech Ltd.
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. GENECAST
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Beijing Lyman Juntai International Medical Technology Development Co.
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Freenome Holdings Inc.
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. Elypta AB
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments